

# Clinical trials of antiarrhythmic drugs for post myocardial infarction in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 amiodarone

Trial	Treatments	Patients	Trials design and methods
<b>early amiodarone vs control</b>			
<b>BASIS , 1990</b> n=98/14 follow-up: 65279;12 mo	amiodarone 1 g for 5 d; then 200 mg/d started within 4 weeks of AMI versus no amiodarone (usual care)	patients with persisting asymptomatic complex arrhythmias after myocardial infarction (Lown class 3 or 4b in >2 of 24 h)	Parallel groups open
<b>Navarro-Lopez , 1993</b> n=115/123 follow-up: 24 mo	amiodarone 600 mg/d for 1 week, 400 mg/d for 1 week then 200 mg/d started 10-30 d after AMI versus no amiodarone	patients who have had MI with a left ventricular ejection fraction of 20 to 45% and >or = 3 ventricular premature complexes per hour (pairs or runs) - 3 VPOs/h, pairs or runs of VT	Parallel groups open Spain
<b>early amiodarone vs placebo</b>			
<b>CAMIAT , 1991</b> n=NA follow-up: 24 mo	amiodarone 10 mg/kg per d for 3 weeks then 300-400 mg/d started 6-45 d after AMI versus placebo	patients with acute myocardial infarction within the previous 6-30 days and >10 VPDs/h for 18 h or a run of VT	Parallel groups double blind
<b>Ceremuzynski , 1992</b> n=305/308 follow-up: 12 mo	amiodarone 800 mg/d for 1 week then 200-400 mg/d started 5-7 d after AMI versus placebo	No need for antiarrhythmic therapy	Parallel groups double blind
<b>Hockings , 1987</b> n=59/70 follow-up: 642 mo	amiodarone 200 mg 3 times daily for 1 wk; then 200 mg/d started <8-10 d after AMI versus placebo	patients with AMI - Absence of VF or VT >3 beats	Parallel groups double blind

## References

### BASIS, 1990:

Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) J Am Coll Cardiol 1990;16:1711-8 [[2254558](#)]

### Navarro-Lopez, 1993:

Navarro-Lpez F, Cosin J, Marrugat J, Guindo J, Bayes de Luna A Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. Am J Cardiol 1993;72:1243-8 [[7504880](#)]

### CAMIAT , 1991:

Cairns JA, Connolly SJ, Gent M, Roberts R Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation 1991;84:550-7 [[1860199](#)]

**Ceremuzynski, 1992:**

Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, Dyduszyński A, Maciejewicz J, Zaleska T, Lazarczyk-Kedzia E Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. *J Am Coll Cardiol* 1992;20:1056-62 [1401602]

**Hockings, 1987:**

Hockings BE, George T, Mahrous F, Taylor RR, Hajar HA Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction. *Am J Cardiol* 1987;60:967-70 [3673913]

## 2 antiarrhythmic

Trial	Treatments	Patients	Trials design and methods
<b>class I drugs vs control</b>			
<b>BASIS , 1990</b> n=100/114 follow-up: 1 year	individualized antiarrhythmic treatment versus no antiarrhythmic therapy	patients with persisting asymptomatic complex arrhythmias after myocardial infarction	Parallel groups open
<b>vs placebo</b>			
<b>CAST I , 1991</b> [NCT00000526] n=NA follow-up: 10 months	encainide or flecainide versus placebo	post MI patients in whom ventricular ectopy could be suppressed with encainide, flecainide	Parallel groups double blind
<b>azimilide vs placebo</b>			
<b>ALIVE , 2004</b> n=NA follow-up: 1y	azimilide 100 mg versus placebo	post-MI patients with depressed LVF	Parallel groups double blind
<b>d,l sotalol vs placebo</b>			
<b>Julian , 1982</b> n=1456 follow-up: 1 year	sotalol 320 mg once daily versus placebo	surviving an acute myocardial infarction	Parallel groups double blind
<b>dofetilide vs placebo</b>			
<b>DIAMOND MI , 1997</b> n=NA follow-up: >12 months	dofetilide versus placebo	patients with acute myocardial infarction within 7 days and left ventricular systolic dysfunction (EF ≤ 35% )	Parallel groups double blind Danish
<b>moricizine vs placebo</b>			
<b>CAST II (late treatment) , 1992</b> n=1155 follow-up:	long term moricizine versus placebo	patient survivor to a myocardial infarction whose ventricular premature depolarizations were adequately suppressed by moricizine	Parallel groups double blind
<b>CAST II (early treatment) , 1992</b> n=665/660 follow-up: 14 days	moricizine for 14 days versus placebo	acute myocardial infarction	Parallel groups double blind

## References

### **BASIS, 1990:**

Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) J Am Coll Cardiol 1990 Dec;16:1711-8 [2254558]

### **CAST I, 1991:**

Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991 Mar 21;324:781-8 [1900101]

### **ALIVE, 2004:**

Pratt CM, Singh SN, Al-Khalidi HR, Brum JM, Holroyde MJ, Marcello SR, Schwartz PJ, Camm AJ The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol 2004 Apr 7;43:1211-6 [15063432]

Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, Karam R, Sonnenblick EH, Brum JM Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004 Mar 2;109:990-6 [14967728]

Camm AJ, Karam R, Pratt CM The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol 1998 Mar 19;81:35D-39D [9537221]

### **Julian, 1982:**

Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997 Mar 8;349:667-74 [9078197]

Julian DG, Prescott RJ, Jackson FS, Szekely P Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982 May 22;1:1142-7 [6122937]

### **DIAMOND MI, 1997:**

Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality ON Dofetilide. Clin Cardiol 1997;20:704-10 [9259163]

### **CAST II (late treatment), 1992:**

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992 Jul 23;327:227-33 [1377359]

### **CAST II (early treatment), 1992:**

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992 Jul 23;327:227-33 [1377359]

## 3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.